Product NDC: | 50222-501 |
Proprietary Name: | TACLONEX |
Non Proprietary Name: | calcipotriene and betamethasone dipropionate |
Active Ingredient(s): | .5; 50 mg/g; ug/g & nbsp; calcipotriene and betamethasone dipropionate |
Administration Route(s): | TOPICAL |
Dosage Form(s): | SUSPENSION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 50222-501 |
Labeler Name: | LEO Pharma Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | NDA022185 |
Marketing Category: | NDA |
Start Marketing Date: | 20080601 |
Package NDC: | 50222-501-66 |
Package Description: | 10 PACKAGE in 1 BOX (50222-501-66) > 2 BOTTLE in 1 PACKAGE > 60 g in 1 BOTTLE |
NDC Code | 50222-501-66 |
Proprietary Name | TACLONEX |
Package Description | 10 PACKAGE in 1 BOX (50222-501-66) > 2 BOTTLE in 1 PACKAGE > 60 g in 1 BOTTLE |
Product NDC | 50222-501 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | calcipotriene and betamethasone dipropionate |
Dosage Form Name | SUSPENSION |
Route Name | TOPICAL |
Start Marketing Date | 20080601 |
Marketing Category Name | NDA |
Labeler Name | LEO Pharma Inc. |
Substance Name | BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE |
Strength Number | .5; 50 |
Strength Unit | mg/g; ug/g |
Pharmaceutical Classes | Vitamin D [Chemical/Ingredient],Vitamin D Analog [EPC],Corticosteroid [EPC],Corticosteroid Hormone Receptor Agonists [MoA] |